+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Pharmaceuticals Industry Deals and Trends in April 2021 - Partnerships, Licensing, Investments, Mergers and Acquisitions (M&A)

  • PDF Icon

    Report

  • June 2021
  • Region: Global
  • GlobalData
  • ID: 5351439
Description Jump to:
The "Pharmaceuticals Industry Deals and Trends in April 2021 - Partnerships, Licensing, Investments, Mergers and Acquisitions (M&A)" report is an essential source of data and trend analysis on partnerships, licensing, mergers and acquisitions (M&As) and financings in the pharmaceuticals industry. The report provides detailed information on partnership and licensing transactions, M&As, equity/debt offerings, private equity, and venture financing registered in the pharmaceuticals industry in April 2021. The report portrays detailed comparative data on the number of deals and their value in the last six months, subdivided by deal types, various therapy areas, and geographies. Additionally, the report provides information on the top financial advisory firms in the pharmaceuticals industry.

Data presented in this report is derived from the publisher’s proprietary in-house Pharma Intelligence Center database and primary and secondary research.

Scope

  • Analysis of the market trends for the pharmaceutical industry in the global arena.
  • Review of deal trends in the cardiovascular, central nervous system, dermatology, ear nose throat disorders, gastrointestinal, genito urinary system and sex hormones, hematological disorders, hormonal disorders, immunology, infectious disease, male health, metabolic disorders, mouth and dental disorders, musculoskeletal, oncology, ophthalmology, respiratory, toxicology, and women's health segments.
  • Analysis of partnerships, licensing, M&As, equity/debt offerings, private equity, and venture financing deals in the pharmaceutical industry.
  • Analysis of therapy areas which are very active in terms of venture capital financing, partnerships, licensing agreements, equity/debt offerings, and M&As.
  • Analysis of deals based on different payment modes, including upfront and milestone payments, primarily in partnerships and licensing agreements in the pharmaceutical industry.
  • Analysis of partnership and licensing deals based on clinical stage of development of products.
  • Summary of the pharmaceutical deals globally in the six months.
  • Information on the top deals happened in the pharmaceutical industry.
  • Geographies covered include - North America, Europe, Asia Pacific, South & Central America, and the Middle East & Africa.
  • League tables of financial advisors in M&As and equity/debt offerings. This includes key advisors such as Morgan Stanley, Credit Suisse, and Goldman Sachs.

Reasons to Buy

  • Enhance your decision making capability in a more rapid and time sensitive manner.
  • Find out the major deal performing segments for investments in your industry.
  • Evaluate the types of companies which are entering into partnership or licensing agreements; divesting and acquiring assets.
  • Identify companies that are aggressively looking to raise capital in the market.
  • Evaluate niche therapy areas that are receiving majority of the upfront and milestone payments in the pharmaceutical industry.
  • Identify the key venture capitalists, who are financing the pharmaceutical and biotech companies.
  • Evaluate the clinical development stages where majority of the partnerships and licensing agreements are happening.
  • Do deals with an understanding of how competitors are financed, and the mergers and partnerships that have shaped the pharmaceutical industry.
  • Identify growth segments and opportunities in each region within the industry.
  • Look for key financial advisors where you are planning to raise capital from the market or for acquisitions within the industry.

Table of Contents

1 Table of Contents
1.1 List of Tables
1.2 List of Figures
2 Pharmaceuticals & Healthcare, Global, Deal Summary
2.1 Pharmaceuticals & Healthcare, Global, Deal Analysis, April 2021
2.2 Pharmaceuticals & Healthcare, Global, Major Deals, April 2021
2.3 Pharmaceuticals & Healthcare, Global, by Type, Number of Deals, April 2021
2.4 Pharmaceuticals & Healthcare, Global, by Type, Deal Values, April 2021
3 Pharmaceuticals and Healthcare, Global, Deals, Summary, by Type
3.1 Pharmaceuticals & Healthcare, Global, M&A, April 2021
3.2 Pharmaceuticals & Healthcare, Global, Equity Offering Deals, April 2021
3.3 Pharmaceuticals & Healthcare, Global, Private Equity and Venture Capital Deals, April 2021
3.4 Pharmaceuticals & Healthcare, Global, Partnership Deals, April 2021
3.5 Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, November 2020- April 2021
3.6 Pharmaceuticals & Healthcare, Global, Partnership Deals by Upfront and Milestone Payments and Deal Values (US$ m), April 2021
3.7 Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, by Upfront and Milestone Payments and Deal Values (US$ m), November 2020- April 2021
3.8 Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, Number Of Deals, November 2020- April 2021
3.9 Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, Deal Values (US$ m), November 2020- April 2021
3.10 Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, by Upfront & Milestone Payments and Deal Values (US$ m), November 2020- April 2021
4 Pharmaceuticals & Healthcare, Global, Licensing Agreements, April 2021
4.1 Pharmaceuticals & Healthcare, Global, Licensing Agreements, April 2021
4.2 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, Upfront and Milestone Payments and Deal Values (US$ m), April 2021
4.3 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Therapy Area, Total Deal Values (US$ m), November 2020- April 2021
4.4 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Therapy Area, Upfront Payments and Milestone Payments (US$ m), November 2020- April 2021
4.5 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Phase, Total Deal Values (US$ m), November 2020- April 2021
4.6 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Phase, Upfront Payments and Milestone Payments (US$ m), November 2020- April 2021
5 Pharmaceuticals & Healthcare, Global, Deal Summary by Therapy Area
5.1 Pharmaceuticals & Healthcare, Global, Oncology Deals, April 2021
5.2 Pharmaceuticals & Healthcare, Global, Central Nervous System Deals, April 2021
5.3 Pharmaceuticals & Healthcare, Global, Infectious Disease Deals, April 2021
5.4 Pharmaceuticals & Healthcare, Global, Cardiovascular Deals, April 2021
5.5 Pharmaceuticals & Healthcare, Global, Immunology Deals, April 2021
5.6 Pharmaceuticals & Healthcare, Global, Metabolic Disorders Deals, April 2021
5.7 Pharmaceuticals & Healthcare, Global, Gastrointestinal Disorders, Deals, April 2021
6 Deal Summary by Geography
6.1 Pharmaceuticals & Healthcare, North America Deals, April 2021
6.2 Pharmaceuticals & Healthcare, Europe, Deals, April 2021
6.3 Pharmaceuticals & Healthcare, Asia-Pacific, Deals, April 2021
6.4 Pharmaceuticals & Healthcare, Rest of the World, Deals, April 2021
7 Pharmaceuticals & Healthcare, Global, Top Financial Advisors
7.1 Pharmaceuticals & Healthcare, Global, Top Financial Advisors, M&A, November 2020- April 2021
7.2 Pharmaceuticals & Healthcare, Global, Top Financial Advisors, Equity Offerings, November 2020- April 2021
8 Further Information
8.1 Methodology
8.2 About the Publisher
8.3 Contact the Publisher
8.4 Disclosure information
8.5 Disclaimer
List of Tables
Table 1: Pharmaceuticals & Healthcare, Global, Deals Summary, Number of Deals and Deal Values (US$ m), November 2020- April 2021
Table 2: Pharmaceuticals & Healthcare, Global, Major Deals, April 2021
Table 3: Pharmaceuticals & Healthcare, Global, Number Of Deals and Deal Values (%), April 2021
Table 4: Pharmaceuticals & Healthcare, Global, M&A, Deals Summary, Number of Deals and Deal Values (US$ m), November 2020- April 2021
Table 5: Pharmaceuticals & Healthcare, Global, Top M&A Deals, April 2021
Table 6: Pharmaceuticals & Healthcare, Global, M&A, Deals Summary, Number of Deals and Deal Values (US$ m), by Therapy Area, November 2020- April 2021
Table 7: Pharmaceuticals & Healthcare, Global, Equity Offerings, Deals Summary, Number of Deals and Deal Values (US$ m), November 2020- April 2021
Table 8: Pharmaceuticals & Healthcare, Global, Top Equity Offering Deals, April 2021
Table 9: Pharmaceuticals & Healthcare, Global, Equity Offering Deals, Deals Summary, Number of Deals and Deal Values (US$ m), November 2020- April 2021
Table 10: Pharmaceuticals & Healthcare, Global, PE/VC, Deals Summary, Number of Deals and Deal Values (US$ m), November 2020- April 2021
Table 11: Pharmaceuticals & Healthcare, Global, Top PE/VC Deals, April 2021
Table 12: Pharmaceuticals & Healthcare, Global, PE/VC Deals by Therapy Area, Deals Summary, November 2020- April 2021
Table 13:Pharmaceuticals & Healthcare, Global, Venture Capital Deals by Stage of Financing, Number Of Deals and Deal Values (%), April 2021
Table 14: Pharmaceuticals & Healthcare, Global, Top Venture Financing Firms, Number of Deals and Deal Values (US$ m), November 2020- April 2021
Table 15: Pharmaceuticals & Healthcare, Global, Top VC Backed Companies, November 2020- April 2021
Table 16: Pharmaceuticals & Healthcare, Global, Partnerships, Number of Deals and Deal Values (US$ m), November 2020- April 2021
Table 17: Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, Number of Deals and Deal Values (US$ m), November 2020- April 2021
Table 18: Pharmaceuticals & Healthcare, Partnership Deals, Upfront and Milestone Payments and Deal Values (US$ m), November 2020- April 2021
Table 19: Pharmaceuticals & Healthcare, Global, Partnerships, Upfront and Milestone Payments and Deal Values (US$ m), April 2021
Table 20: Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, Upfront and Milestone Payments and Deal Values (US$ m), November 2020- April 2021
Table 21:Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, November 2020- April 2021
Table 22: Pharmaceuticals & Healthcare, Global, Partnership Deals by Upfront and Milestone Payment and Deal values (US$ m), November 2020- April 2021
Table 23: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, Deals Summary, Number of Deals and Deal Values (US$ m), November 2020- April 2021
Table 24: Pharmaceuticals & Healthcare, Global, Licensing Agreements, Deals Summary, Upfront and Milestone Payments and Deal Values (US$ m), November 2020- April 2021
Table 25: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Therapy Area, Number of Deals and Deal Values (US$ m), November 2020- April 2021
Table 26: Pharmaceuticals & Healthcare, Global, Licensing Agreements by Therapy Area, by Upfront and Milestone Payments (US$ m), April 2021
Table 27: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Phase, November 2020- April 2021
Table 28: Pharmaceuticals & Healthcare, Global, Licensing Agreements by Therapy Area, by Upfront and Milestone Payments and Deal Values (US$ m), April 2021
Table 29: Pharmaceuticals & Healthcare, Global, Top Licensing Agreement Deals by Value, April 2021
Table 30: Pharmaceuticals & Healthcare, Global, Top Licensing Agreement Deals by Total Upfront Payments, April 2021
Table 31: Pharmaceuticals & Healthcare, Global, Top Licensing Agreement Deals by Total Milestone Payment, April 2021
Table 32: Pharmaceuticals & Healthcare, Global, Oncology, Deals Summary, Number of Deals and Deal Values (US$ m), November 2020- April 2021
Table 33: Pharmaceuticals & Healthcare, Global, Central Nervous System, Deals Summary, Number of Deals and Deal Values (US$ m), November 2020- April 2021
Table 34: Pharmaceuticals & Healthcare, Global, Infectious Diseases, Deals Summary, Number of Deals and Deal Values (US$ m), November 2020- April 2021
Table 35: Pharmaceuticals & Healthcare, Global, Cardiovascular, Deals Summary, Number of Deals and Deal Values (US$ m), November 2020- April 2021
Table 36: Pharmaceuticals & Healthcare, Global, Immunology, Deals Summary, Number of Deals and Deal Values (US$ m), November 2020- April 2021
Table 37: Pharmaceuticals & Healthcare, Global, Metabolic Disorders, Deals Summary, Number of Deals and Deal Values (US$ m), November 2020- April 2021
Table 38: Pharmaceuticals & Healthcare, Global, Gastrointestinal, Deals Summary, Number of Deals and Deal Values (US$ m), November 2020- April 2021
Table 39: Pharmaceuticals & Healthcare, North America, Deals Summary, Number of Deals and Deal Values (US$ m), November 2020- April 2021
Table 40: Pharmaceuticals & Healthcare, Europe, Deals Summary, Number of Deals and Deal Values (US$ m), November 2020- April 2021
Table 41: Pharmaceuticals & Healthcare, Asia-Pacific, Deals Summary, Number of Deals and Deal Values (US$ m), November 2020- April 2021
Table 42: Pharmaceuticals & Healthcare, Rest of the World, Deals Summary, Number of Deals and Deal Values (US$ m), November 2020- April 2021
Table 43: Pharmaceuticals & Healthcare, Top Financial Advisors, M&A, Number of Deals and Deal Values (US$ m), November 2020- April 2021
Table 44: Pharmaceuticals & Healthcare, Global Top Financial Advisors, Equity Offerings, Number of Deals and Deal Values (US$ m), November 2020- April 2021
List of Figures
Figure 1: Pharmaceuticals & Healthcare, Global, Number of Deals and Deal Values (US$ m), November 2020- April 2021
Figure 2: Pharmaceuticals & Healthcare, Global, Number of Deals (%), April 2021
Figure 3: Pharmaceuticals & Healthcare, Global, Deal Values (%), April 2021
Figure 4: Pharmaceuticals & Healthcare, Global, M&As, Number of Deals and Deal Values (US$ m), November 2020- April 2021
Figure 5: Pharmaceuticals & Healthcare, Global, M&As by Therapy Area, Number of Deals and Deal Values (US$ m), by Therapy Area, November 2020- April 2021
Figure 6: Pharmaceuticals & Healthcare, Global, Equity Offering Deals, Number of Deals and Deal Values (US$ m), November 2020- April 2021
Figure 7: Pharmaceuticals & Healthcare, Global, Equity Offering Deals by Therapy Area, Number of Deals and Deal Values (US$ m), November 2020- April 2021
Figure 8: Pharmaceuticals & Healthcare, Global, Private Equity and Venture Capital, Number of Deals and Deal Values (US$ m), November 2020- April 2021
Figure 9: Pharmaceuticals & Healthcare, Global, PE/VC Deals by Therapy Area, Number of Deals and Deal Values (US$ m), by Therapy Area, November 2020- April 2021
Figure 10: Pharmaceuticals & Healthcare, Global, Venture Capital Deals by Stage of Financing, Number of Deals (%), April 2021
Figure 11: Pharmaceuticals & Healthcare, Global, Venture Capital Deals by Stage of Financing, Deal Values (%), April 2021
Figure 12: Pharmaceuticals & Healthcare, Global, Top Venture Financing Firms, Number of Deals and Deal Values (US$ m), November 2020- April 2021
Figure 13: Pharmaceuticals & Healthcare, Global, Partnerships, Number of Deals and Deal Values (US$ m), November 2020- April 2021
Figure 14: Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, Number of Deals and Deal Values (US$ m), November 2020- April 2021
Figure 15: Pharmaceuticals & Healthcare, Global, Partnership Deals, Upfront and Milestone Payments and Deal Values (US$ m), November 2020- April 2021
Figure 16: Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, Upfront and Milestone Payments and Deal Values (US$ m), November 2020- April 2021
Figure 17: Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, November 2020- April 2021
Figure 18: Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, November 2020- April 2021
Figure 19: Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, by Upfront & Milestone Payments and Deal Values (US$ m), November 2020- April 2021
Figure 20: Pharmaceuticals & Healthcare, Global, Licensing Agreements, Number of Deals and Deal Values (US$ m), November 2020- April 2021
Figure 21: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, Upfront and Milestone Payments and Deal Values (US$ m), November 2020- April 2021
Figure 22: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Therapy Area, Number of Deals and Deal Values (US$ m), November 2020- April 2021
Figure 23: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Therapy Area, Upfront and Milestone Payments and Deal Values (US$ m), November 2020- April 2021
Figure 24: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Phase, Number of Deals, November 2020- April 2021
Figure 25: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Phase, Deal Values (US$ m), November 2020- April 2021
Figure 26: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Phase, by Upfront and Milestone Payments and Deal Values (US$ m), April 2021
Figure 27: Pharmaceuticals & Healthcare, Global, Oncology, Number of Deals and Deal Values (US$ m), November 2020- April 2021
Figure 28: Pharmaceuticals & Healthcare, Global, Central Nervous System, Number of Deals and Deal Values (US$ m), November 2020- April 2021
Figure 29: Pharmaceuticals & Healthcare, Global, Infectious Diseases, Number of Deals and Deal Values (US$ m), November 2020- April 2021
Figure 30: Pharmaceuticals & Healthcare, Global, Cardiovascular, Number of Deals and Deal Values (US$ m), November 2020- April 2021
Figure 31: Pharmaceuticals & Healthcare, Global, Immunology, Number of Deals and Deal Values (US$ m), November 2020- April 2021
Figure 32: Pharmaceuticals & Healthcare, Global, Metabolic Disorders, Deals Summary, Number of Deals and Deal Values (US$ m), November 2020- April 2021
Figure 33: Pharmaceuticals & Healthcare, Global, Gastrointestinal, Deals Summary, Number of Deals and Deal Values (US$ m), November 2020- April 2021
Figure 34: Pharmaceuticals & Healthcare, North America, Number of Deals and Deal Values (US$ m), November 2020- April 2021
Figure 35: Pharmaceuticals & Healthcare, Europe, Number of Deals and Deal Values (US$ m), November 2020- April 2021
Figure 36: Pharmaceuticals & Healthcare, Asia-Pacific, Number of Deals and Deal Values (US$ m), November 2020- April 2021
Figure 37: Pharmaceuticals & Healthcare, Rest of the World, Number of Deals and Deal Values (US$ m), November 2020- April 2021
Figure 38: Pharmaceuticals & Healthcare, Global, Top Financial Advisors, M&A, Number of Deals and Deal Values (US$ m), November 2020- April 2021
Figure 39: Pharmaceuticals & Healthcare, Global, Top Financial Advisors, Equity Offerings, Number of Deals and Deal Values (US$ m), November 2020- April 2021

Related Topics

Related Reports

Medication Adherence Market - Growth, Trends, COVID-19 Impact, and Forecasts (2023 - 2028) - Product Image

Medication Adherence Market - Growth, Trends, COVID-19 Impact, and Forecasts (2023 - 2028)

  • Report
  • 120 Pages
  • Global
From
Licensing Deals in Pharmaceuticals 2019-2024 - Product Image

Licensing Deals in Pharmaceuticals 2019-2024

  • Report
  • 1300 Pages
  • Global
From
Genitourinary Drugs Market - Growth, Trends, and Forecasts (2023 - 2028) - Product Image

Genitourinary Drugs Market - Growth, Trends, and Forecasts (2023 - 2028)

  • Report
  • 113 Pages
  • Global
From
Pharmaceutical Suppositories Global Market Report 2024 - Product Image

Pharmaceutical Suppositories Global Market Report 2024

  • Report
  • 175 Pages
  • Global
From
Medication Adherence Global Market Report 2024 - Product Image

Medication Adherence Global Market Report 2024

  • Report
  • 175 Pages
  • Global
From
Copyright © 2002-2024 Research and Markets. All Rights Reserved.